Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03401112 · ClinicalTrials.gov registry record · Phase 2
A Study of IMR-687 in Adult Participants With Sickle Cell Anemia (Homozygous HbSS or Sickle-β0 Thalassemia)
A Phase 2 study, sponsored by Cardurion Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 100
- Enrollment target
NCT03401112 is a Phase 2 study that has completed, run by Cardurion Pharmaceuticals. The registered enrollment target is 100 participants.
The verdict
NCT03401112, a Phase 2 study, has completed, sponsored by Cardurion Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 100 participants
- Enrollment target
Study Summary
Study of IMR-687 in adult participants with sickle cell anemia (SCA) (homozygous HbSS or sickle-β0 thalassemia).
Interventions
- DRUG Placebo
- DRUG IMR-687
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2018-01-26 |
| Est. Completion | 2020-08-28 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03401112
The ClinicalTrials.gov registry entry for NCT03401112 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Cardurion Pharmaceuticals, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03401112 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03401112 about?
NCT03401112 is a clinical study titled "A Study of IMR-687 in Adult Participants With Sickle Cell Anemia (Homozygous HbSS or Sickle-β0 Thalassemia)". Study of IMR-687 in adult participants with sickle cell anemia (SCA) (homozygous HbSS or sickle-β0 thalassemia).
What is the current status of trial NCT03401112?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 100 participants. The study started on 2018-01-26. Estimated completion is 2020-08-28.
What interventions are being tested in trial NCT03401112?
The interventions under investigation include: Placebo (DRUG), IMR-687 (DRUG).
Who is sponsoring clinical trial NCT03401112?
This trial is sponsored by Cardurion Pharmaceuticals, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.